What is the role of natural killer (NK) cells in the treatment of non-Hodgkin lymphoma/B-cell lymphoma?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Unlike anti-CD19 CAR T-cell therapy, treatment with natural killer (NK) cells that have been modified to express an anti-CD19 has been shown to promote no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. A phase 1/2 trial of HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood, in 11 patients with relapsed or refractory CD19-positive cancer, reported response to treatment in the majority of cases, without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. [23]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!